Predict your next investment

Venture Capital
hamiltonbioventures.com

See what CB Insights has to offer

Investments

34

Portfolio Exits

4

Funds

2

About Hamilton BioVentures

Hamilton BioVentures is a venture capital firm (with $100 million under management) investing in talented entrepreneurs bringing new Life Science technology enterprises to market. Hamilton BioVentures invests in companies developing dramatically better treatments (biopharmaceuticals and medical devices) for major human diseases and other medical conditions. Our investments generally take the form of direct equity in early-stage companies located on the West Coast..

Hamilton BioVentures Headquarter Location

990 Highland Drive

Solana Beach, California, 92075-2438,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Hamilton BioVentures News

Splash Pharmaceuticals Announces Financing to Advance Ovarian Cancer Clinical Trial

May 22, 2018

Splash Pharmaceuticals, Inc. (“Splash”), a private biopharmaceutical company that develops novel cancer therapies, announced completion of a financing round to support the ongoing clinical trial of SPL-108. The round was oversubscribed and was led by existing investors Hamilton BioVentures (“Hamilton”) and Solstice Capital. The proceeds will support Splash’s clinical trial in platinum-resistant ovarian cancer patients. Splash is developing a pipeline of novel therapeutics that target CD44 with the goal to achieve dramatic and durable responses in cancer patients. The first of these therapies, SPL-108, has demonstrated significant activity in animal models including ovarian, breast, endometrial, prostate, liver and brain cancers. SPL-108 has also demonstrated activity in multiple Phase I and II clinical trials in gynecological cancers with an excellent safety profile. Splash believes that combining SPL-108 with other therapies will provide even greater activity which is the basis for the current clinical trial. “We are very pleased to close this financing round and are particularly gratified by the strong support from our existing investors who know the story best,” said Dr. David Nelson, President and CEO of Splash Pharmaceuticals. “We are excited by the breadth and depth of preclinical and clinical data that we have generated in support of our latest clinical trial in ovarian cancer. SPL-108 holds great promise for many types of cancer and we look forward to testing this clinical hypothesis with our latest trial.” “Hamilton is excited to participate in this financing round,” said Dr. Kerry Dance, Chairman of Hamilton BioVentures. “The unique mechanism of action of SPL-108 provides a compelling possibility of achieving durable responses, which is something that has remained elusive in many recent breakthrough cancer therapies.” About Splash Pharmaceuticals Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is actively seeking Pharma partners to accelerate its novel clinical programs. For more information, visit www.splashpharma.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20180521006108/en/ Splash Pharmaceuticals

Hamilton BioVentures Investments

34 Investments

Hamilton BioVentures has made 34 investments. Their latest investment was in Splash Pharmaceuticals as part of their Series D on May 5, 2018.

CBI Logo

Hamilton BioVentures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/22/2018

Series D

Splash Pharmaceuticals

Yes

1

9/23/2011

Series C - II

Celerus Diagnostics

$10M

No

11/12/2010

Series D

Ceregene

$11.5M

No

4/14/2009

Series D

Subscribe to see more

$99M

Subscribe to see more

0

3/19/2007

Series D

Subscribe to see more

$99M

Subscribe to see more

0

Date

5/22/2018

9/23/2011

11/12/2010

4/14/2009

3/19/2007

Round

Series D

Series C - II

Series D

Series D

Series D

Company

Splash Pharmaceuticals

Celerus Diagnostics

Ceregene

Subscribe to see more

Subscribe to see more

Amount

$10M

$11.5M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

0

0

Hamilton BioVentures Portfolio Exits

4 Portfolio Exits

Hamilton BioVentures has 4 portfolio exits. Their latest portfolio exit was Ceregene on August 26, 2013.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/26/2013

Acquired

$99M

2

6/19/2007

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

11/11/2005

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

2/20/2004

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

8/26/2013

6/19/2007

11/11/2005

2/20/2004

Exit

Acquired

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

0

0

0

Hamilton BioVentures Fund History

2 Fund Histories

Hamilton BioVentures has 2 funds, including Hamilton Apex Technology Ventures LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2002

Hamilton Apex Technology Ventures LP

Early-Stage Venture Capital

Closed

$97M

1

6/1/2002

Hamilton BioVentures

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2002

6/1/2002

Fund

Hamilton Apex Technology Ventures LP

Hamilton BioVentures

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$97M

$99M

Sources

1

10

Hamilton BioVentures Team

6 Team Members

Hamilton BioVentures has 6 team members, including current Controller, Ann Collins.

Name

Work History

Title

Status

Ann Collins

Controller

Current

Richard J. Crosby

Managing Director

Current

Kerry Dance

Managing Director

Current

Elliot Parks

Ventana Capital Management, Qed Technologies, and Myelos Neurosciences

Managing Director

Current

D. Elliot Parks

Ventana Capital Management, Qed Technologies, and Myelos Neurosciences

Managing Director

Current

Name

Ann Collins

Richard J. Crosby

Kerry Dance

Elliot Parks

D. Elliot Parks

Work History

Ventana Capital Management, Qed Technologies, and Myelos Neurosciences

Ventana Capital Management, Qed Technologies, and Myelos Neurosciences

Title

Controller

Managing Director

Managing Director

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.